Compare URGN & PRLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | URGN | PRLB |
|---|---|---|
| Founded | 2004 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Fabrications |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | 2016 | 2011 |
| Metric | URGN | PRLB |
|---|---|---|
| Price | $43.55 | $80.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 2 |
| Target Price | $29.29 | ★ $53.00 |
| AVG Volume (30 Days) | ★ 692.0K | 251.8K |
| Earning Date | 05-06-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | N/A | ★ 0.33 |
| Revenue | ★ $1,128,000.00 | N/A |
| Revenue This Year | $129.09 | $8.56 |
| Revenue Next Year | $70.96 | $6.89 |
| P/E Ratio | ★ N/A | $233.67 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.86 | $38.48 |
| 52 Week High | $41.92 | $83.15 |
| Indicator | URGN | PRLB |
|---|---|---|
| Relative Strength Index (RSI) | 80.04 | 61.12 |
| Support Level | $17.89 | $71.59 |
| Resistance Level | N/A | $82.76 |
| Average True Range (ATR) | 2.14 | 2.75 |
| MACD | 0.14 | 0.08 |
| Stochastic Oscillator | 97.16 | 94.24 |
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
Proto Labs Inc is an on-demand manufacturer of custom parts for prototyping and short-run production. The company offers developers and engineers quick-turn production services to reduce the time to market. The Lab uses injection molding, computer numerical control machining, and 3-D printing, and sheet metal to manufacture custom parts for its clients. The company services clients' needs for prototype solutions, parts for testing procedures, bridge production capabilities during disruptions in manufacturing processes, limited-quantity requests, and end-of-life production support. Geographically, a majority of the company's revenue is derived from the United States and the rest from Europe.